Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Hanahan

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
BMC Cancer|May 23, 2002
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerZhu Alexander Cao, Dylan Daniel, Douglas Hanahan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesisChristopher W Chiu, Hiroaki Nozawa, Douglas Hanahan
Cancer Cell|November 16, 2013
A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapyMichele De Palma, George Coukos, Douglas Hanahan
Nature Reviews. Cancer|October 25, 2024
Convergent inducers and effectors of T cell paralysis in the tumour microenvironmentDouglas Hanahan, Olivier Michielin, Mikael J Pittet
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2019
A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasisIacovos P Michael, Sadegh Saghafinia, Douglas Hanahan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2011
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionElizabeth Allen, Ian B Walters, Douglas Hanahan
Plos Medicine|February 1, 2008
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targetingKristian Pietras, Jessica Pahler, Gabriele Bergers, et al.
Genes & Development|September 19, 2007
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancerDouglas Hanahan, Erwin F Wagner, Richard D Palmiter
Cancer Cell|October 18, 2005
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsOriol Casanovas, Daniel J Hicklin, Gabriele Bergers, et al.
Cancer Cell|June 15, 2010
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelatorSeiko Ishida, Frank McCormick, Karen Smith-McCune, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
BMC Cancer|May 23, 2002
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerZhu Alexander Cao, Dylan Daniel, Douglas Hanahan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesisChristopher W Chiu, Hiroaki Nozawa, Douglas Hanahan
Cancer Cell|November 16, 2013
A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapyMichele De Palma, George Coukos, Douglas Hanahan
Nature Reviews. Cancer|October 25, 2024
Convergent inducers and effectors of T cell paralysis in the tumour microenvironmentDouglas Hanahan, Olivier Michielin, Mikael J Pittet
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2019
A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasisIacovos P Michael, Sadegh Saghafinia, Douglas Hanahan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2011
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionElizabeth Allen, Ian B Walters, Douglas Hanahan
Plos Medicine|February 1, 2008
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targetingKristian Pietras, Jessica Pahler, Gabriele Bergers, et al.
Genes & Development|September 19, 2007
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancerDouglas Hanahan, Erwin F Wagner, Richard D Palmiter
Cancer Cell|October 18, 2005
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsOriol Casanovas, Daniel J Hicklin, Gabriele Bergers, et al.
Cancer Cell|June 15, 2010
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelatorSeiko Ishida, Frank McCormick, Karen Smith-McCune, et al.
Pageof 11